{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancies&page=6", "query": { "condition": "Advanced Solid Tumor Malignancies", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 3365, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancies&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancies&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T21:02:55.166Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04186637", "title": "An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "ALPN-202", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alpine Immune Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 62, "start_date": "2020-06-02", "completion_date": "2023-02-28", "has_results": false, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Lafayette, Indiana + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04186637" }, { "nct_id": "NCT05861895", "title": "HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, Adult" ], "interventions": [ { "name": "HF158K1 / 1.4 g lipid dose", "type": "DRUG" }, { "name": "HF158K1 / 2.2 g lipid dose", "type": "DRUG" }, { "name": "HF158K1 / 2.9 g lipid dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HighField Biopharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 84, "start_date": "2023-12-12", "completion_date": "2027-12-23", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05861895" }, { "nct_id": "NCT04092673", "title": "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "eFT226", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-10-25", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 14, "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04092673" }, { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" }, { "nct_id": "NCT01263145", "title": "MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2011-01-05", "completion_date": "2012-10-19", "has_results": false, "last_update_posted_date": "2017-08-25", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01263145" }, { "nct_id": "NCT04189445", "title": "Futibatinib in Patients With Specific FGFR Aberrations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumor", "Advanced or Metastatic Gastric or Gastroesophageal Cancer", "Myeloid or Lymphoid Neoplasms (MLN)" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2020-08-05", "completion_date": "2024-11-11", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 11, "location_summary": "Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04189445" }, { "nct_id": "NCT01929941", "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Hodgkin's Lymphoma", "NHL (Non-Hodgkin Lymphoma)", "Pancreatic Cancer", "Breast Cancer", "UC (Ureter and Urethera)", "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "INCB047986", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-09", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01929941" }, { "nct_id": "NCT02535312", "title": "Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Advanced Peritoneal Malignant Mesothelioma", "Advanced Pleural Malignant Mesothelioma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Refractory Malignant Solid Neoplasm", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methoxyamine", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2016-03-08", "completion_date": "2026-10-15", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02535312" }, { "nct_id": "NCT01357330", "title": "Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "SAR245408 (XL147)", "type": "DRUG" }, { "name": "MSC1936369B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-05", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2016-04-01", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01357330" }, { "nct_id": "NCT00658970", "title": "Evaluation of KX2-391 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "KX2-391", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Athenex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2007-11", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-10-09T21:02:55.166Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00658970" } ] }